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Age-dependent differences in pulmonary 
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Abstract 
Background: Results from preclinical studies suggest that age‑dependent differences in host defense and the pul‑
monary renin–angiotensin system (RAS) are responsible for observed differences in epidemiology of acute respiratory 
distress syndrome (ARDS) between children and adults. The present study compares biomarkers of host defense and 
RAS in bronchoalveolar lavage (BAL) fluid from neonates, children, adults, and older adults with ARDS.
Methods: In this prospective observational study, we enrolled mechanical ventilated ARDS patients categorized 
into four age groups: 20 neonates (< 28 days corrected postnatal age), 29 children (28 days–18 years), 26 adults 
(18–65 years), and 17 older adults (> 65 years of age). All patients underwent a nondirected BAL within 72 h after 
intubation. Activities of the two main enzymes of RAS, angiotensin converting enzyme (ACE) and ACE2, and levels of 
biomarkers of inflammation, endothelial activation, and epithelial damage were determined in BAL fluid.
Results: Levels of myeloperoxidase, interleukin (IL)‑6, IL‑10, and p‑selectin were higher with increasing age, whereas 
intercellular adhesion molecule‑1 was higher in neonates. No differences in activity of ACE and ACE2 were seen 
between the four age groups.
Conclusions: Age‑dependent differences in the levels of biomarkers in lungs of ARDS patients are present. Especially, 
higher levels of markers involved in the neutrophil response were found with increasing age. In contrast to preclinical 
studies, age is not associated with changes in the pulmonary RAS.
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Background
Maturation and aging-induced changes in biological 
pathways involved in the host response to injurious pul-
monary and non-pulmonary insults may in part account 
for observed differences in prevalence and outcome 
of acute respiratory distress syndrome (ARDS) among 
different age groups [1]. Preclinical studies using animal 
models for ARDS have suggested age-dependent differ-
ences in pulmonary edema, neutrophil infiltration, and 
alveolar damage after identical insults [2]. In particular, 
the pulmonary renin angiotensin system (RAS) seems to 
play a key role in these differences [3–5]. With increas-
ing age, the balance between the two main enzymes of 
the pulmonary RAS, angiotensin converting enzyme 
(ACE) and its natural counteracting enzyme ACE2, shifts 
toward the lung injurious axis (i.e., ACE), an imbalance 
that has been associated with aggravating inflammation 
and increased lung injury [6].
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The current challenge is to confirm these findings of 
animal studies in the human clinical setting. We there-
fore investigated biomarkers of inflammation, endothe-
lial activation, epithelial damage, and enzymatic activities 
of the pulmonary RAS in bronchoalveolar lavage (BAL) 
fluid collected from ARDS patients at different ages. We 
hypothesized that aging is associated with an intensified 
host response and a shift in the balance from ACE2 to 
ACE in ARDS.
Methods
Study design
This prospective cohort study was performed at the neo-
natal, pediatric, and adult intensive care units (ICUs) of 
the Academic Medical Center, a university hospital in 
Amsterdam, the Netherlands. This study was conducted 
as a substudy of the Molecular Diagnosis and Risk Strati-
fication of Sepsis (MARS) project (NCT01905033), a 
prospective observational cohort study in the adult ICUs 
of two tertiary teaching hospitals [7, 8]. Patients admitted 
to the ICU and fulfilling systemic inflammatory response 
syndrome (SIRS) criteria were included for BAL fluid 
sampling. To address the current hypothesis, a similar 
study protocol was used in the neonatal and pediatric 
ICU patient population (no. NL42386.018.12). Both pro-
tocols were approved by the Institutional Review Board, 
and written informed consent was provided by legal 
guardians of the patient prior to enrollment. All patients 
were included between January 2012 and May 2016.
Inclusion and exclusion criteria
For the present analysis, we included all patients with 
ARDS, defined according to the criteria stated by the 
American-European Consensus Conference on ARDS 
[9]. Based on the updated Berlin Definition for ARDS, 
we reclassified patients into mild  (PaO2/FiO2 ≤ 300), 
moderate  (PaO2/FiO2 ≤ 200), and severe ARDS  (PaO2/
FiO2 ≤ 100) [10]. To prevent confounding due to differ-
ences in ARDS definitions between the age groups, we 
did not use the recently developed age-specific Pediatric 
Acute Lung Injury Consensus and Montreux Definition 
for ARDS [11, 12].
Additional inclusion criteria were two or more of 
the SIRS criteria on the day of ICU admission and an 
expected ICU stay of more than 24 h, as these were the 
two single inclusion criteria of the MARS project. Exclu-
sion criteria were readmission or transfer from another 
ICU, absence of an arterial line, and receiving antibiotics 
for more than 48 h prior to admission. Additional exclu-
sion criteria for neonatal and pediatric patients were a 
body weight of less than 1 kg, immune compromised sta-
tus, chronic respiratory failure, neuromuscular diseases, 
cyanotic congenital heart disease, or severe congenital 
pulmonary abnormalities, and mechanical ventilation 
within 7  days before eligibility for enrollment into the 
study. In addition, neonates with postmenstrual age less 
than 32  weeks and postnatal age less than 7  days were 
excluded to avoid confounding by neonatal respiratory 
distress syndrome or transient tachypnea of the newborn.
Patients were stratified into four groups according to 
age: neonates (< 28  days corrected postnatal age), chil-
dren (28  days–18  years), adult (18–65  years), and older 
adults (> 65 years of age).
Main outcome measures
The primary endpoints were BAL fluid levels of the 
inflammatory biomarkers interleukin (IL)-6, IL-10, mye-
loperoxidase (MPO), the endothelial activation mark-
ers inter-cellular adhesion molecule (ICAM)-1, vascular 
endothelial growth factor (VEGF), p-selectin, the mark-
ers of epithelial damage clara cell (CC) protein 16, soluble 
receptor for advanced glycation end-products (sRAGE), 
and protein levels. In addition, ACE and ACE2 activities 
in BAL fluid were measured. These markers were chosen 
based on previous studies indicating that these biomark-
ers are involved in the main pathophysiological pathways 
of ARDS and all were reported to be affected by age [2, 
13–18].
Clinical data collection
Demographics, predisposing factors for ARDS, ventilator 
settings at start of ventilation, oxygenation parameters at 
onset of ARDS and within the first 24 h after intubation, 
age-appropriate severity of illness scores [19–21], ICU 
mortality, and ventilator-free days and alive at day 28 
(VFD-28) were recorded. Details on data collection and 
definitions are described in the Additional file 1.
BAL fluid sampling and measurements
BAL fluid was obtained within 72  h after intubation. In 
neonates and pediatric patients, the nondirected lav-
age was performed with two aliquots of sterile isotonic 
saline (1 ml/kg; with a maximum of 10 ml) according to 
guidelines of the European Respiratory Group Taskforce 
on Bronchoalveolar Lavage in Children [22] and in adults 
with one aliquot (fixed volume of 15 ml). No estimate of 
dilution was used in analysis of the data in accordance 
with the guidelines of the European Respiratory Society 
(ERS) Task Force Group on Bronchoalveolar Lavage in 
Children and Adults [22, 23]. A sample was considered 
invalid if the protein level was below the detection limit 
of the assay. For details on collection and assays, see the 
Additional file 1.
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Analysis plan
First, we described baseline characteristic of ARDS 
patients stratified by the four age groups. Then, we 
compared the BAL fluid levels of several biomark-
ers of the host response and ACE and ACE2 activities 
between the four age groups. To avoid confounding 
due to differences in dilutions, we also expressed ACE2 
and ACE activities as a ratio ACE2/ACE. Finally, we 
determined the correlations between host response 
biomarker levels and ACE and ACE2 activities and the 
ACE2/ACE ratio. A post hoc analysis was performed to 
explore the effect of severity of ARDS on the relation 
between the age group and the biomarker levels.
Statistical analysis
All data are presented as median ± interquartile range 
(IQR). Group comparisons were evaluated by one-way 
analysis of variance for normally or Kruskall–Wallis test 
for non-normally distributed data. A chi-squared test 
was used for categorical variables. Group differences 
for host response biomarker levels and ACE and ACE2 
activities were tested by post hoc Dunn’s test with Bon-
ferroni correction for multiple comparisons. The corre-
lations between ACE, ACE2 activity, ACE2/ACE ratio, 
and biomarkers were tested by the Spearman’s rho test. 
The effect of ARDS severity on the association between 
age and the biomarker levels was explored by linear 
regression models, with the age group as the independ-
ent variable, the biomarkers as the dependent variable 
and  PaO2-to-FiO2 ratio as a potential confounder.
Statistical analysis was performed using R-statistics 
2.15.0 (R Foundation, Vienna, Austria, www.r-proje 
ct.org). A p value less than 0.05 was considered statisti-
cally significant.
Results
Clinical characteristics of patients
We enrolled 92 ARDS patients (Fig. 1). Patient charac-
teristics are presented in Table 1. In all four age groups, 
ARDS was considered to have a direct cause in most 
cases. A detailed description of predisposing factors is 
provided in Additional file 1: Table S1.
Most neonates (65%) were classified as having severe 
ARDS, while the proportion of severe ARDS was much 
lower among the other age groups (9%, 35%, and 29% 
in children, adults, and older adults, respectively). The 
median  PaO2-to-FiO2 ratio at onset of ARDS was sig-
nificantly lower in neonates when compared to chil-
dren, adults, and older adults. Of note, after 24  h, 
median  PaO2-to-FiO2 ratio increased in all age groups 
and there were no differences between the age groups 
anymore.
In general, tidal volumes  (VT), when expressed in ml/
kg ideal body weight, were comparable among the four 
age groups. Independent of age, patients were all venti-
lated with  VT < 8 ml/kg ideal body weight. In contrast, 
PEEP was significantly higher in adults and older adults 
when compared to neonates and children. In neonates, 
high-frequency oscillation (HFO) ventilation was most 
frequently used.
Mortality rates differed significantly between the age 
groups (p < 0.001), with the highest mortality rate in 
adults (48%) and no mortality in children (Table 1).
Host response biomarker levels in BAL fluid
BAL fluid levels of MPO were significantly lower in neo-
nates and children when compared to adults and older 
adults (Fig.  2a). In addition, significant lower levels of 
IL-6, IL-10, and p-selectin were found in neonates when 
compared to the other age groups (Fig. 2b, c, Additional 
file  1: Fig. S1a). Protein levels and CC-16 levels showed 
a similar trend, albeit not significant after correction 
for multiple testing (Additional file  1: Fig. S1c and d). 
Fig. 1 Flowchart. * ARDS was defined by the Berlin definition; ** A 
sample was considered invalid if no proteins could be measured. 
ARDS = acute respiratory distress syndrome ¶ 1 premature neonate, 
36 weeks at time of inclusion. The exclusion criteria were not 
exclusive. In case a patient fulfilled more than one exclusion criteria, 
only one was chosen to report. AB antibiotics, ARDS acute respiratory 
distress syndrome, BALF bronchoalveolar lavage fluid, No IC no 
informed consent, SIRS systemic inflammatory response syndrome
Page 4 of 9Schouten et al. Ann. Intensive Care            (2019) 9:55 
Interestingly, the endothelial activation marker ICAM-1 
showed an opposite trend, with significantly higher lev-
els in neonates compared to adults and older adults 
(Fig.  2d). VEGF and sRAGE showed no age-related dif-
ferences (Additional file  1: Fig. S1b and e). A post hoc 
analysis showed that the association between increasing 
age and increased levels of MPO, IL-10, p-selectin and 
the decreased levels of ICAM-1 remained significant 
after correction for severity of ARDS (Additional file  1: 
Table S3).
BAL fluid ACE and ACE2 activities
Comparison of BAL fluid ACE activities (Fig.  3a), 
ACE2 activities (Fig.  3b), and ACE2/ACE ratios 
(Fig.  3c) between the four age groups revealed no sig-
nificant differences. Independent of age, the ACE2/
ACE ratio showed a weak correlation with protein levels 
(rho = 0.30, p < 0.01). There were no correlations between 
the ACE2/ACE ratio and the host response biomarkers 
(Additional file  1: Table  S2). There was a weak positive 
correlation between ACE activities and increased lev-
els of the inflammatory markers MPO, IL-6, epithelial 
damage marker sRAGE and endothelial activation 
marker p-selectin, while ACE2 showed a weak positive 
correlation with increased levels of the endothelial acti-
vation markers ICAM-1, VEGF, and p-selectin (Addi-
tional file 1: Table S2).
Discussion
In this study, we found an increase in pulmonary inflam-
matory mediators involved in the neutrophil response 
with increasing age. No age-dependent differences in 
ACE and ACE2 were seen, suggesting that the age-
dependent differences in the pulmonary host response 
are not mediated by changes in pulmonary RAS.
This is the first study in which the pulmonary host 
response in ARDS is compared between patients of dif-
ferent ages. It is a unique cohort as we included not only 
children and adults, but also neonates and older adults, 
clinically important subgroups of ARDS patients who 
are frequently excluded from clinical studies. Mechani-
cal ventilation practice was applied according to proto-
cols stressing lung-protective ventilator settings, and we 
Table 1 Baseline characteristics and outcome
Variables Neonates Children Adults Older adults p value
N = 20 N = 29 N = 26 N = 17
Demographics
 Age (years), median [IQR] 0.03 [0.00–0.05] 0.21 [0.12–0.82] 55 [48–61] 74 [70–77] NA
 Male, n (%) 10 (50) 20 (62) 14(54) 9 (53) 0.85
 Race, (Caucasian), n (%) 18 (90) 25 (86) 20 (77) 15 (88) 0.64
 Severity of illness score, median [IQR] 16 [5–22]a 4.4 [4.0–5.0]b 85 [66–125]c 87 [79–106]c NA
Predisposing  factorsd
 Direct hit, n (%) 14 (70) 27 (93) 16 (61) 12 (70) < 0.001
 Indirect hit, n (%) 6 (30) 2 (7) 10 (39) 5 (30) 0.09
Oxygenation
 PaO2/FiO2 at onset, median [IQR] 88 [64–129] 137 [115–190] 124 [83–153] 146 [85–182] 0.03
 PaO2/FiO2 after 24 h, median [IQR] 187 [138–229] 188 [140–227] 188 [150–215] 205 [177–281] 0.41
Berlin classification
 PaO2/FiO2 200‑300 (mild), n (%) 2 (12) 3 (9) 3 (12) 4 (24) 0.58
 PaO2/FiO2 100‑200 (moderate), n (%) 4 (24) 26 (81) 14 (54) 8 (47) 0.002
 PaO2/FiO2 < 100 (severe), n (%) 11 (65) 3 (9) 9 (35) 5 (29) 0.001
Study procedure
 Timing BAL from time of ARDS diagnosis, days, 
median [IQR]
1 [0–1] 1 [0–1] 1 [0–1] 1 [0–1] 0.56
At start of ventilation
 Tidal volume (ml/kg), median [IQR] 7.0 [5.0–7.3] 6.9 [5.6–7.9] 6.6 [4.9–7.8] 5.1 [4.5–6.1] 0.07
 PEEP  (cmH2O), median [IQR] 7 [6–8] 6 [5–7] 8 [5–10] 10 [8–12] 0.002
 High‑frequency oscillation, n (%) 10 (50) 0 (0) 0 (0) 0 (0) NA
Outcome
 Mortality at ICU, n (%) 2 (10) 0(0) 11 (42) 3 (18) < 0.001
 VFD and alive at day 28*, days, median [IQR] 21 [18–25] 18 [17–20] 17 [0–24] 21 [15–25] 0.18
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strictly followed standardized operating procedures to 
obtain BAL fluid.
We found age-dependent differences, especially in 
markers known to be involved the neutrophil response 
(MPO, IL-6, and IL-10), one of the hallmarks of ARDS 
[24]. Levels of these markers were significantly lower in 
neonates/children compared to adults/older adults. Pre-
clinical studies also showed that neutrophil influx into 
the lung and the accompanying inflammatory mediator 
response is lower in neonatal and juvenile animals com-
pared to adult and older animals [2, 15, 25–27]. A murine 
model of ARDS showed differences in the activation 
of genetic networks of several inflammatory pathways 
(e.g., cell migration and interleukin activity) involved 
in the pathophysiology of ARDS between juvenile and 
adult animals [15]. Synergistic interactions between pul-
monary injurious hits, i.e., LPS and mechanical ventila-
tion, were observed in the adult animals as a result of 
coordinated changes in gene expression of these path-
ways. These interactions did not occur in the juveniles. 
Maturational differences in the innate immune system 
are predominately studied in neonates, while fewer data 
exist from older children. In neonates, the absolute num-
ber of neutrophils is significantly lower than in adults 
Fig. 2 Markers of inflammation, endothelial activation and epithelial activation in bronchoalveolar lavage fluid of ARDS patients. a Myeloperoxidase 
(MPO), b interleukin (IL)‑6, c p‑selectin, d intercellular adhesion molecule (ICAM)‑1 levels in bronchoalveolar lavage (BAL) fluid of ARDS patients 
stratified by four age groups. Horizontal bars represent the median. Group differences were tested with a Dunn’s test with Bonferroni correction for 
multiple comparisons. A p value less than 0.05 was considered statistical significant
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due to immaturity of the proliferative pool and they 
demonstrate reduced responsiveness and diminished 
extravasation [28]. It is suggested that the latter is caused 
by a lower expression of adhesion molecules, such as 
p-selectin and less production of chemotactic mediators 
by resident inflammatory cells [28]. Indeed, we found 
lower levels of the adhesion molecule p-selectin and the 
chemotactic cytokines (IL-6, IL-10) in the BAL fluid of 
neonates with ARDS. Moreover, these levels tended to 
increase with increasing age. In septic neonates, children 
and adults with similar age-dependent differences in lev-
els of adhesion molecules have been described in blood 
plasma [29].
In contrast, we found the highest levels of the other 
adhesion molecule ICAM-1 in neonates. ICAM-1 is an 
adhesion molecule on endothelial cells and is known to 
play an important role in neutrophil tracking into the 
lung [28]. Levels of adhesion molecules in BAL fluid 
are the result of both protein expression and proteo-
lytic activity of sheddases [29]. P-selectin and ICAM-1 
are known to be cleaved by different enzymes, and age-
related differences in proteolytic activity of sheddases 
have been reported [30, 31]. This may account for the 
discrepancy we found between p-selectin and ICAM-1 
levels. Moreover, in our study, neonates had the lowest 
Fig. 3 ACE and ACE2 activity in bronchoalveolar lavage fluid of ARDS patients. a ACE and b ACE2 activity in bronchoalveolar lavage (BAL) fluid of 
ARDS patients stratified by four age groups. c ACE2/ACE ratio. Horizontal bars represent the median. Group differences were tested with a Dunn’s 
test with Bonferroni correction for multiple comparisons. A p value less than 0.05 was considered statistical significant. ACE angiotensin converting 
enzyme
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 PaO2-to-FiO2 ratio, which is known to increase levels of 
ICAM-1 [32].
In contrast to the evidence in preclinical studies, our 
data could not confirm an age-dependent role of the pul-
monary RAS in the development and course of ARDS [6]. 
An important reason may be the wide individual varia-
tion in the levels of ACE and ACE2 activities within the 
age groups. This could have interfered with the possi-
bility to detect small, but clinically relevant, age-related 
differences. A recent clinical trial showed similar vari-
ability of RAS activation in adult ARDS patients [33] and 
speculated that this may be caused by both intrinsic (i.e., 
genetic) variability of RAS activity and heterogeneity of 
ARDS [34]. In addition, our study included only those 
patients who had already developed ARDS and needed to 
be ventilated, while in preclinical studies, enzyme activi-
ties are measured just a few hours after the initial insult. 
Temporal changes in RAS activation are known to exist 
[35]. Above all, independent of the age groups, we found 
no correlation between ACE2/ACE ratio and the host 
response biomarkers. Moreover, ACE and ACE2 activi-
ties were only weakly correlated with some of the inflam-
matory markers and endothelial activation markers. This 
suggests that the pulmonary RAS may not be the leading 
pathway in the inflammatory response in humans with 
ARDS. It must be noted that preclinical studies investi-
gating ARDS have repeatedly failed in their translation 
into clinical practice and these models may not reflect 
the complex pathophysiology of ARDS in patients [36]. 
Accordingly, studies have shown that the host responses 
in murine models correlate poorly with human condi-
tions [37]. As a consequence, usefulness and applicability 
of these models are an important matter of debate [38].
Our study has several limitations. Although the largest 
study ever, the sample size per age group was still rela-
tively small. This could explain, at least in part, the lack of 
differences between the three age groups. Indeed, several 
age-dependent differences in biomarker levels became 
nonsignificant after correction for multiple testing. This 
suggests that the current study may have been underpow-
ered. Second, differences in dilution of the lavage fluid 
may have influenced the results. Studies have indicated 
that an important part of the variability in fluid recovery 
is due to the way lavage fluid is obtained [22, 23]. There-
fore, only trained physicians could perform the lavage in 
this study, and a standardized operating procedure was 
strict followed. According to the guidelines of the Euro-
pean Respiratory Group Taskforce on Bronchoalveolar 
Lavage in Children, we did not correct for the effects 
of dilution or return yield in our analyses [22]. There 
is currently no reliable indicator which can be used for 
correction [22]. Therefore, we expressed the pulmonary 
RAS enzymatic activities as a ratio to avoid confounding. 
However, BAL fluid levels of the host response biomark-
ers could still have been influenced by dilution differ-
ences. Though, based on the opposite directions of the 
effects of age found in levels of the different biomarkers, 
these age-related differences found are unlikely to be fully 
explained by differences in dilution. Third, we investi-
gated only biomarker levels in the alveolar compartment. 
Therefore, we were not able to determine whether the 
differences in biomarker concentrations are due to age-
related differences in the local host response or maybe 
caused by leakage and reflect age-related variation in 
the systemic host response. Finally, we applied the Ber-
lin definition of ARDS in all age groups and not the Pedi-
atric Acute Lung Injury Consensus criteria for pediatric 
[11] or the Montreux criteria for neonatal ARDS [12] to 
prevent bias due to differences in the definition of ARDS. 
There are important discrepancies between the Berlin 
definition and these age-specific criteria which might 
have given another distribution of the ARDS severity 
classes. But, this would not have influenced our out-
comes, i.e., levels of host response biomarkers and RAS 
enzyme activities.
Conclusions
In conclusion, this study found differences in BAL fluid 
levels of biomarkers involved in the neutrophil response 
between the age groups, which may form an explana-
tion for the previously observed age-related differences 
in epidemiology of ARDS. However, no differences in 
the pulmonary RAS were found between the different 
age groups. This suggests a role for other underlying 
pathophysiological mechanisms. Understanding the age-
related differences in the host response during ARDS is 
essential for the development of effective therapy.
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